Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma LSE:MTPH London Ordinary Share GB00BRTL9B63 ORD 0.005P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 44.00p 43.00p 45.00p 44.00p 44.00p 44.00p 15,605 07:35:33
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.9 -29.3 -56.0 - 26.88

Midatech Pharma (MTPH) Latest News

More Midatech Pharma News
Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Share Charts

1 Year Midatech Pharma Chart

1 Year Midatech Pharma Chart

1 Month Midatech Pharma Chart

1 Month Midatech Pharma Chart

Intraday Midatech Pharma Chart

Intraday Midatech Pharma Chart

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date Time Title Posts
16/1/201823:04Midatech Pharma (MTPH) sees 10-fold increase76
03/1/201712:41Midatech Pharma PLC181

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-01-22 15:52:4342.008,4603,553.20O
2018-01-22 14:23:3643.004,4681,921.24O
2018-01-22 12:57:0144.402,027899.98O
2018-01-22 12:52:2244.40650288.60O
View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

Midatech Pharma Daily Update: Midatech Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 44p.
Midatech Pharma has a 4 week average price of 34.50p and a 12 week average price of 34.50p.
The 1 year high share price is 152.50p while the 1 year low share price is currently 34.50p.
There are currently 61,084,125 shares in issue and the average daily traded volume is 10,348 shares. The market capitalisation of Midatech Pharma is £26,877,015.
jamtomorrow2: The share price is 45p for a reason. One failed trial, a loss making acquisition and two approvals to conduct a trial after 3 years as a public company. That’s all folks. But at least one shareholder seems happy.
jamtomorrow2: MTD201 study approved!! Somewhat misleading headline! I was under the impression that it had been approved to commence ages ago. Nobody ever said the hold-up was due to not having EU approval. So the previously quoted reason for the hold-up of problems relating to gearing up to production levels at the Spanish lab was basically as misleading as the heading to today’s announcement. So when is this wretched trial actually going to start? It’s delay after delay after delay. No wonder the share price is so bombed out. Also why do we hear nothing about the success or otherwise of the compansionate UK program re childrens brain cancer? This had been going on for a couple of years now. If successful you’d have thought they’d be singing out the good news from the rooftops.
jamtomorrow2: Loss of £20m and one failed drug and a share price down 50%. A really great year!
thomasthetank1: Read Panmure Gordon & Co's note on MIDATECH PHARMA, out this morning, by visiting hxxps:// "More good news this morning. Positive pharmacokinetic data from Midatech’s Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome demonstrate a favourable profile against the reference and market leader Sandostatin LAR Depot (Novartis). This paves the way towards IND submission and bio-equivalence in human studies expected in late 2016 and today’s news adds further weight and momentum to the company’s recent news flow. With significant headroom on the current share price ..."
thomasthetank1: Read Panmure's note on Midatech Pharma (MTPH), out this morning, by visiting … “Today’s FY15 results see revenues of £1.38m ahead of our expectations (PGe £1.30m, 2014: £0.16m) and, adjusting for one-off listing/acquisition items, the strong performance is also reflected at the bottom-line, with adjusted pre-tax loss of £9.9m vs PGe £10.6m loss. Delivery of this kind, during a period of high activity, reflects well on management capabilities and bandwidth. The parallel strands of commercial and pipeline development bode well for the long-term risk and growth profile of the business and we note strong revenues from marketed products in the first three months of 2016 with trading ‘slightly ahead of market expectations’. We retain our earnings forecasts unchanged for now but will look to future updates with respect to potential headroom on our forecasts. In the meantime, our view remains that there is significant headroom on the current share price…”
hutch_pod: Good interview. Liked hearing his view on the share price and Dara shareholder profit taking. Hope April delivers good progress.
hutch_pod: Did you see this from 17th? hTtp:// High time for an update on this article: the merger has been approved, the ADR's have been issued, but the idea so far hasn't worked out like I had planned. One of the risks highlighted in the article was: "Midatech's ADRs trading in tandem with its Ordinary Shares could cause the price of the ADRs to go up, but the same mechanism could obviously also cause the price of the Ordinary Shares in the UK to go down." Unfortunately, this is what happened. Since the deal was completed the MTPH share price in London took a bath and has now dropped close to 25% in about two weeks, making this deal a nightmare for the UK holders. I indicated in the article MTPH was illiquid and unshortable; I knew the shares in London would likely drop as a result of ADR-holders converting and selling, explaining some of the premium to the US price. But I hadn't expected an <20M take over to cause MTPH to shed >30M in market cap which in itself is of course fundamentally questionable; Midatech + DARA combined is now worth less than Midatech itself used to do. Also, trading volumes were horrendously low. I had expected MTPH-management, or any of its many experienced institutional investors, to see this coming based on the illiquidity of MTPH-shares, and to have at least something of contingency plan ready. Apparently so far they didn't. One would assume experienced investors like Neil Woodford (who holds an 18% stake through Woodford Investment Management) would not allow his fund to lose millions in a few days on trading volumes of about 40K $ without stepping in. One would also assume he, or any one of the other holders being hung out to dry, still will. It wouldn't take much. Anyway, with regards to ADR conversion: no US listed ADR I'm aware of trades at a discount to its UK listed peers, and MTP won't either in the mid term
njw2: The problem is quite simple, there is a major seller in the US line ( probably someone being stopped out from the total bulls up with the confusion on the merger )and until this is dealt with the share price collapse will continue. Maybe if someone at the company had a brain they would find the seller and take him out. Until that happens the share price will continue to collapse and there is no bottom on this.
deltrotter: They could well be in a closed period though tools with further news pending. The trading update in Q1 should make very interesting reading. I am peeved with the share price and their investor relations, but I am not peeved with their strategy and the execution of it.
Midatech Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180123 06:19:02